JP2013520166A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520166A5 JP2013520166A5 JP2012553874A JP2012553874A JP2013520166A5 JP 2013520166 A5 JP2013520166 A5 JP 2013520166A5 JP 2012553874 A JP2012553874 A JP 2012553874A JP 2012553874 A JP2012553874 A JP 2012553874A JP 2013520166 A5 JP2013520166 A5 JP 2013520166A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- polypeptide
- rage
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims 28
- 102000037865 fusion proteins Human genes 0.000 claims 28
- 229920001184 polypeptide Polymers 0.000 claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims 22
- 230000035772 mutation Effects 0.000 claims 9
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 238000003776 cleavage reaction Methods 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000007017 scission Effects 0.000 claims 6
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 230000013595 glycosylation Effects 0.000 claims 5
- 238000006206 glycosylation reaction Methods 0.000 claims 5
- 102000049409 human MOK Human genes 0.000 claims 5
- 102000004961 Furin Human genes 0.000 claims 4
- 108090001126 Furin Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010012655 Diabetic complications Diseases 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims 2
- 102220598894 Reduced folate transporter_N58Q_mutation Human genes 0.000 claims 2
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 2
- 108020001756 ligand binding domains Proteins 0.000 claims 2
- 102200054322 rs121909342 Human genes 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005230 Leg Ulcer Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000036252 glycation Effects 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30570610P | 2010-02-18 | 2010-02-18 | |
| US61/305,706 | 2010-02-18 | ||
| USPCT/US2010/032270 | 2010-04-23 | ||
| PCT/US2010/032270 WO2011102845A1 (en) | 2010-02-18 | 2010-04-23 | Rage fusion protein compositions and methods of use |
| PCT/US2010/053157 WO2011102860A1 (en) | 2010-02-18 | 2010-10-19 | Rage fusion protein compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013520166A JP2013520166A (ja) | 2013-06-06 |
| JP2013520166A5 true JP2013520166A5 (enExample) | 2013-12-05 |
Family
ID=44483217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012553874A Pending JP2013520166A (ja) | 2010-02-18 | 2010-10-19 | Ｒａｇｅ融合タンパク質及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20130142792A1 (enExample) |
| EP (1) | EP2536750A1 (enExample) |
| JP (1) | JP2013520166A (enExample) |
| CA (1) | CA2789244A1 (enExample) |
| TW (1) | TW201141507A (enExample) |
| WO (2) | WO2011102845A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200044138A (ko) | 2011-06-24 | 2020-04-28 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 |
| JP2015504675A (ja) * | 2012-01-10 | 2015-02-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用 |
| WO2013164694A1 (en) | 2012-04-30 | 2013-11-07 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| PL2970512T3 (pl) | 2013-03-12 | 2019-03-29 | Biocon Limited | Immunomodulujące białka fuzyjne i sposoby ich otrzymywania |
| CA2947396C (en) * | 2014-04-28 | 2021-10-19 | Eisai R&D Management Co., Ltd. | Lyophilized formulation of hgf |
| RU2747977C2 (ru) | 2016-03-17 | 2021-05-18 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Способ получения активного фактора роста гепатоцитов (hgf) |
| WO2020056379A1 (en) * | 2018-09-14 | 2020-03-19 | BioAge Labs, Inc. | Rage fusion proteins with improved stability and ligand binding affinity and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
| US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
| US6825164B1 (en) | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
| JP4336498B2 (ja) * | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| EA010594B1 (ru) * | 2001-05-24 | 2008-10-30 | Займодженетикс, Инк. | Слитые белки taci-иммуноглобулина |
| JP4685764B2 (ja) * | 2003-04-10 | 2011-05-18 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変 |
| WO2004100890A2 (en) * | 2003-05-09 | 2004-11-25 | The Trustees Of Columbia University In The City Of New York | Rage g82s-related methods and compositions for treating inflammatory disorders |
| CN1805743A (zh) | 2003-05-20 | 2006-07-19 | 特兰斯泰克制药公司 | 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂 |
| CN1993378A (zh) * | 2004-08-03 | 2007-07-04 | 转化技术制药公司 | Rage融合蛋白及使用方法 |
| WO2006119510A2 (en) * | 2005-05-04 | 2006-11-09 | Receptor Biologix, Inc. | Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same |
| BRPI0711193A2 (pt) * | 2006-05-05 | 2013-06-18 | Transtech Pharma Inc | proteÍnas de fusço rage, formulaÇÕes e mÉtodos de uso dos mesmos |
| EP2158210B1 (en) * | 2007-06-14 | 2015-12-09 | Galactica Pharmaceuticals, Inc. | Rage fusion proteins |
| DE102008037312B3 (de) | 2008-08-11 | 2010-02-18 | Emz-Hanauer Gmbh & Co. Kgaa | Elektrischer Schalter, insbesondere in Mikroschalter-Bauform |
-
2010
- 2010-04-23 WO PCT/US2010/032270 patent/WO2011102845A1/en not_active Ceased
- 2010-10-19 WO PCT/US2010/053157 patent/WO2011102860A1/en not_active Ceased
- 2010-10-19 JP JP2012553874A patent/JP2013520166A/ja active Pending
- 2010-10-19 CA CA2789244A patent/CA2789244A1/en not_active Abandoned
- 2010-10-19 EP EP10773766A patent/EP2536750A1/en not_active Withdrawn
- 2010-10-19 US US13/062,395 patent/US20130142792A1/en not_active Abandoned
-
2011
- 2011-02-18 TW TW100105575A patent/TW201141507A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI760333B (zh) | Ｇｄｆ１５融合蛋白及其用途 | |
| JP2011501959A5 (enExample) | ||
| Ward et al. | The three dimensional structure of the type I insulin-like growth factor receptor | |
| CN1114876C (zh) | 用计算机辅助鉴定红细胞生成素的潜在模拟物的方法及由该方法筛选出化合物 | |
| JP2008508882A5 (enExample) | ||
| US20130288372A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
| JP2011525363A5 (enExample) | ||
| JP2022046510A (ja) | 血清アルブミン結合フィブロネクチンｉｉｉ型ドメイン | |
| JP2009201525A5 (enExample) | ||
| WO2014165093A9 (en) | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto | |
| JP2010529860A5 (enExample) | ||
| CN101389648A (zh) | 肽胃泌酸调节素衍生物 | |
| CN113292646B (zh) | Glp-1/胰高血糖素双重激动剂融合蛋白 | |
| US20160237133A1 (en) | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use | |
| KR20210024081A (ko) | 당뇨병을 위한 gip/glp1 공효능제의 사용 방법 | |
| EP3368059A1 (en) | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs | |
| CN118598939B (zh) | Kim-1特异性结合的肾靶向多肽及其在制备用于治疗肾脏疾病的药物中的应用 | |
| US20220119448A1 (en) | Artificial recombinant protein for improving performance of active protein or polypeptide and use thereof | |
| JP2016019527A (ja) | Ｂ細胞活性化因子の拮抗物質、その調製方法及び利用法 | |
| US20110230401A1 (en) | Insulin fusion polypeptides | |
| WO2015000413A1 (zh) | 长效降血糖融合蛋白 | |
| WO2007146171A2 (en) | Purified high molecular weight adiponectin and uses thereof | |
| Tutone et al. | Leptin and the OB-receptor as anti-obesity target: recent in silico advances in the comprehension of the protein-protein interaction and rational drug design of anti-obesity lead compounds | |
| CN116478298A (zh) | Glp-1和gdf15的融合蛋白及其用途 | |
| CN114617956B (zh) | 一种高效降糖的蛋白质药物 |